DE69840495D1 - Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben - Google Patents

Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben

Info

Publication number
DE69840495D1
DE69840495D1 DE69840495T DE69840495T DE69840495D1 DE 69840495 D1 DE69840495 D1 DE 69840495D1 DE 69840495 T DE69840495 T DE 69840495T DE 69840495 T DE69840495 T DE 69840495T DE 69840495 D1 DE69840495 D1 DE 69840495D1
Authority
DE
Germany
Prior art keywords
deletes
production
pharmaceutical form
dispersion properties
rapid dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840495T
Other languages
German (de)
English (en)
Inventor
Jaedeok Yoo
Sandeep Kumar
Donald C Monkhouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of DE69840495D1 publication Critical patent/DE69840495D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69840495T 1997-02-20 1998-02-20 Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben Expired - Lifetime DE69840495D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3888397P 1997-02-20 1997-02-20
US3828497P 1997-02-20 1997-02-20
PCT/US1998/003256 WO1998036738A1 (en) 1997-02-20 1998-02-20 Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same

Publications (1)

Publication Number Publication Date
DE69840495D1 true DE69840495D1 (de) 2009-03-12

Family

ID=26715043

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840495T Expired - Lifetime DE69840495D1 (de) 1997-02-20 1998-02-20 Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben

Country Status (9)

Country Link
US (3) US6471992B1 (enExample)
EP (1) EP0973507B1 (enExample)
JP (3) JP4563516B2 (enExample)
AT (1) ATE421318T1 (enExample)
AU (1) AU736912B2 (enExample)
CA (1) CA2281473C (enExample)
DE (1) DE69840495D1 (enExample)
ES (1) ES2318869T3 (enExample)
WO (1) WO1998036738A1 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4563516B2 (ja) * 1997-02-20 2010-10-13 マサチューセッツ インスティテュート オブ テクノロジー 迅速分散性を示す投与剤形、その使用法並びにその製造方法
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US6284270B1 (en) * 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
EP1301177A2 (en) * 2000-07-10 2003-04-16 Therics, Inc. Method and materials for controlling migration of binder liquid in a powder
HRP20031057B1 (hr) * 2001-06-28 2013-05-31 Ucb Farchim Sa, Z.I. Planchy Tableta koja sadrži cetirizin i pseudoefedrin
EA005537B1 (ru) * 2001-07-10 2005-04-28 Тева Фармасьютикал Индастриес Лтд. Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата
US20030099708A1 (en) * 2001-10-29 2003-05-29 Therics, Inc Printing or dispensing a suspension such as three-dimensional printing of dosage forms
JP4845340B2 (ja) * 2001-10-29 2011-12-28 マサチューセッツ インスティテュート オブ テクノロジー 三次元プリント投薬形態のような物品の一軸圧縮のためのシステムおよび方法
DE60323482D1 (de) 2002-05-06 2008-10-23 Massachusetts Inst Technology Diffusionskontrollierte arzneiform sowie herstellungsmethode mittels dreidimensionalem drucken
MXPA05005528A (es) 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
ES2378452T3 (es) 2004-09-21 2012-04-12 Hypnion, Inc. �?cido 3-[4-(dibenzo[b,f][1,4]oxazepin-11-il)-piperazin-1-il]-2,2¿dimetil-propanoico para usarlo en el tratamiento de trastornos del sueño
US7829000B2 (en) * 2005-02-25 2010-11-09 Hewlett-Packard Development Company, L.P. Core-shell solid freeform fabrication
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
ES2500165T3 (es) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
ES2842334T3 (es) 2007-10-20 2021-07-13 Athenex Inc Composiciones farmacéuticas para modular una cascada de cinasas y métodos de uso de las mismas
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
EP2493457B1 (en) 2009-10-30 2017-08-09 IX Biopharma Ltd Fast dissolving solid dosage form
ES2634551T3 (es) * 2010-04-03 2017-09-28 Praful Doshi Métodos para revestir una lente de contacto
US8692001B2 (en) 2010-10-27 2014-04-08 Dynamix Pharmaceuticals Ltd. Sulfonamides for the modulation of PKM2
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
WO2012122370A2 (en) 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
US20120302609A1 (en) 2011-05-25 2012-11-29 Dynamix Pharmaceuticals Ltd. Pyrazolines for the Modulation of PKM2
JP6054379B2 (ja) 2011-06-07 2016-12-27 クレベクセル・ファーマＣｌｅｖｅｘｅｌ Ｐｈａｒｍａ キナーゼをモジュレートするための組成物および方法
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
US9245061B2 (en) * 2012-04-25 2016-01-26 Shapeways, Inc. Weight-based identification of three dimensional printed parts
AU2012379005B2 (en) 2012-05-02 2017-12-21 Newmarket Pharmaceuticals Llc Pharmaceutical compositions for direct systemic introduction
IN2014DN11205A (enExample) 2012-06-20 2015-10-02 Eutropics Pharmaceuticals Inc
CN105263907B (zh) 2012-08-30 2018-11-20 阿西纳斯公司 作为蛋白质酪氨酸激酶调节剂的n-(3-氟苄基)-2-(5-(4-吗啉代苯基)吡啶-2-基)乙酰胺
WO2014116770A1 (en) 2013-01-23 2014-07-31 Arx, Llc Production of unit dose constructs
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
ES2761407T3 (es) 2013-03-15 2020-05-19 Aprecia Pharmaceuticals LLC Forma de dosificación rápidamente dispersable de topiramato
EP2968354B1 (en) * 2013-03-15 2019-11-13 Aprecia Pharmaceuticals LLC Rapidly dispersible dosage form of oxcarbazepine
HK1216513A1 (zh) * 2013-03-15 2016-11-18 阿普雷奇亚制药有限责任公司 包含左乙拉西坦的快速分散劑型
WO2014176389A1 (en) 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
JP6233996B2 (ja) 2013-08-16 2017-11-22 ザ エクスワン カンパニー ３次元印刷される金属鋳造用鋳型及び同鋳型の製造方法
US20160243621A1 (en) 2013-10-17 2016-08-25 The Exone Company Three-Dimensional Printed Hot Isostatic Pressing Containers and Processes for Making Same
EP3086921B1 (en) * 2013-12-23 2019-07-31 The Exone Company Methods and systems for three-dimensional printing utilizing a jetted-particle binder fluid
ES2745763T3 (es) 2013-12-23 2020-03-03 The Exone Co Métodos y sistemas para la impresión en tres dimensiones utilizando múltiples fluidos aglutinantes
US11001048B2 (en) 2013-12-23 2021-05-11 The Exone Company Method of three-dimensional printing using a multi-component build powder
EP3137113A4 (en) * 2014-04-30 2017-03-22 Blaesi, Aron H. Melt-processed polymeric cellular dosage form
US20170120329A1 (en) 2014-05-29 2017-05-04 The Exone Company Process for Making Nickel-Based Superalloy Articles by Three-Dimensional Printing
WO2016011098A2 (en) 2014-07-17 2016-01-21 The Exone Company Methods and apparatuses for curing three-dimensional printed articles
PT3220891T (pt) 2014-11-21 2019-10-31 Biohaven Pharm Holding Co Ltd Formulação sublingual de riluzol
EP3227109B1 (en) 2014-12-03 2020-08-19 The Exone Company Process for making densified carbon articles by three dimensional printing
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
EP3108874A1 (en) * 2015-06-26 2016-12-28 TRB Chemedica AG Ophthalmologic pharmaceutical composition
WO2017075096A1 (en) * 2015-10-26 2017-05-04 Blaesi Aron H Solid dosage form immediate drug release and apparatus and method for manufacture thereof
US11129798B2 (en) 2016-08-19 2021-09-28 Aron H. Blaesi Fibrous dosage form
EP3429564A1 (en) * 2016-03-18 2019-01-23 Grünenthal GmbH Combination of drugs having different potency
MA45334A (fr) 2016-03-24 2019-01-30 Probiotical Spa Composition bactérienne d'acide lactique pour le traitement d'infections vaginales bactériennes par gardnerella vaginalis et, éventuellement, d'infections fongiques concurrentes
ES2992002T3 (es) * 2016-04-06 2024-12-05 Astellas Pharma Inc Moldeo tridimensional de elución rápida, filamento para moldeo tridimensional de elución rápida y material para moldeo tridimensional de elución rápida
EP3981392A1 (en) 2016-05-05 2022-04-13 Triastek, Inc. Controlled release dosage form
HRP20240617T1 (hr) 2016-05-20 2024-07-19 Biohaven Therapeutics Ltd. Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
CN110023310B (zh) 2016-08-12 2024-05-10 阿西纳斯公司 用于调节激酶级联的联芳组合物和方法
US11040491B2 (en) 2016-10-19 2021-06-22 Shapeways, Inc. Systems and methods for identifying three-dimensional printed objects
CA3045043A1 (en) 2016-12-31 2018-07-05 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US12102721B2 (en) 2017-01-26 2024-10-01 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
US11602502B2 (en) 2017-02-24 2023-03-14 Hewlett-Packard Development Company, L.P. Three-dimensional (3D) printing a pharmaceutical tablet
ES2958616T3 (es) 2017-03-08 2024-02-12 Cinrx Pharma Llc Formulaciones farmacéuticas de floroglucinol y trimetilfloroglucinol
US10435576B2 (en) 2017-05-26 2019-10-08 Infinite Material Solutions, Llc Water soluble polymer compositions
RS66277B1 (sr) 2017-11-12 2025-01-31 Biohaven Therapeutics Ltd Primena prolekova riluzola za lečenje ataksija
CN108066302B (zh) * 2017-12-28 2020-09-11 无限极（中国）有限公司 一种快速分散固体制剂的制备方法及制备的快速分散固体制剂
US10350822B1 (en) 2018-01-09 2019-07-16 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof
CN116270513A (zh) 2018-01-09 2023-06-23 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
DE102018107585B3 (de) * 2018-03-29 2019-03-28 Universität Rostock Vorrichtung zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen mit Wirkstoffdepots, sowie Verfahren zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen
CN115154440A (zh) 2018-06-27 2022-10-11 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
US11278501B2 (en) 2018-10-15 2022-03-22 Aprecia Pharmaceuticals LLC Method and system for forming a dosage form within a packaging
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
US12103229B2 (en) * 2019-03-15 2024-10-01 Ricoh Company, Ltd. Jettable temporary binders to create removable support materials
JP7287032B2 (ja) 2019-03-20 2023-06-06 株式会社リコー シート、シート積層体、医薬品、シートの製造方法、及びシート積層体の製造方法
AU2020277668A1 (en) * 2019-05-21 2021-11-25 Dfe Pharma Gmbh & Co. Kg Lactose powder bed three dimensional printing
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
EP3789015A1 (en) * 2019-09-05 2021-03-10 Universität Innsbruck Fast consolidating compounds
TWI734309B (zh) * 2019-12-19 2021-07-21 水星生醫股份有限公司 滲透性噴塗製作藥錠裝置
US12371581B2 (en) 2020-03-25 2025-07-29 Infinite Material Solutions, Llc High performance water soluble polymer compositions
MX2022016117A (es) 2020-06-26 2023-04-05 Aprecia Pharmaceuticals LLC Tabletas rapidamente orodispersables que tienen una cavidad interior.
US20230390193A1 (en) 2020-10-30 2023-12-07 Triastek, Inc. Gastroretentive pharmaceutical dosage form
WO2022155564A1 (en) 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
WO2024108082A1 (en) 2022-11-18 2024-05-23 Aprecia Pharmaceuticals LLC Orodispersive dosage forms containing droxidopa
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5204055A (en) 1989-12-08 1993-04-20 Massachusetts Institute Of Technology Three-dimensional printing techniques
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
ES2081564T3 (es) 1991-01-31 1996-03-16 Texas Instruments Inc Metodo y sistema para la fabricacion, controlada por ordenador, de objetos tridimensionales a partir de datos de ordenador.
ATE138563T1 (de) * 1991-12-20 1996-06-15 Pfizer Poröse geformte abgabevorrichtung und verfahren zur herstellung derselbe
JP2521612B2 (ja) * 1992-05-20 1996-08-07 ウエイ・ミン・フアーマシユーテイカル・マニユフアクチヤリング・カンパニー・リミテツド 直接錠剤形成助剤
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
DE4303846A1 (de) * 1993-02-10 1994-08-11 Merck Patent Gmbh Verfahren zur Herstellung einer S-Ibuprofen enthaltenden Tablette
JP3233638B2 (ja) 1993-07-09 2001-11-26 アール．ピー． シェーラー コーポレイション 凍結乾燥された薬投与形状物の製造方法
US6176874B1 (en) 1993-10-18 2001-01-23 Masschusetts Institute Of Technology Vascularized tissue regeneration matrices formed by solid free form fabrication techniques
US6280771B1 (en) 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
US5490962A (en) 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
US5503785A (en) 1994-06-02 1996-04-02 Stratasys, Inc. Process of support removal for fused deposition modeling
US5633021A (en) 1994-10-19 1997-05-27 Bpm Technology, Inc. Apparatus for making a three-dimensional article
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5560927A (en) * 1995-07-28 1996-10-01 Isp Investments Inc. Co-processing method for making a free-flowing compressible powder and tablet therefrom
US5653925A (en) * 1995-09-26 1997-08-05 Stratasys, Inc. Method for controlled porosity three-dimensional modeling
JP4563516B2 (ja) 1997-02-20 2010-10-13 マサチューセッツ インスティテュート オブ テクノロジー 迅速分散性を示す投与剤形、その使用法並びにその製造方法
DE19940944B4 (de) * 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen

Also Published As

Publication number Publication date
US20030133975A1 (en) 2003-07-17
JP2001512488A (ja) 2001-08-21
AU736912B2 (en) 2001-08-02
AU6331498A (en) 1998-09-09
EP0973507A1 (en) 2000-01-26
CA2281473A1 (en) 1998-08-27
ES2318869T3 (es) 2009-05-01
US9463160B2 (en) 2016-10-11
ATE421318T1 (de) 2009-02-15
WO1998036738A1 (en) 1998-08-27
JP5091910B2 (ja) 2012-12-05
EP0973507A4 (en) 2006-08-23
EP0973507B1 (en) 2009-01-21
JP4563516B2 (ja) 2010-10-13
US20120207929A1 (en) 2012-08-16
US6471992B1 (en) 2002-10-29
CA2281473C (en) 2007-01-16
JP2009215305A (ja) 2009-09-24
US9114072B2 (en) 2015-08-25
JP2010120938A (ja) 2010-06-03

Similar Documents

Publication Publication Date Title
DE69840495D1 (de) Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
DE10224607B4 (de) Filmförmige, zerfallsfähige Zubereitungen zur Wirkstofffreisetzung und Verfahren zu deren Herstellung
DE69704426D1 (de) Verfahren zur herstellung von medizinischem kaugummi mit einem guten geschmack, enthaltend eine einschlussverbindung
ATE260651T1 (de) Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
ATE204468T1 (de) Mittel zur verzögerten freisetzung von menschlichem wachstumshormon
DE69919863T8 (de) Stabilgelmischung in form einer mischung eines öligen gels und eines wässrigen gels
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
YU66600A (sh) Farmaceutski preparati koji mogu da budu gelirani
IL76256A (en) Controlled-release medical preparations and method for their preparation
DE3850823D1 (de) System zur Freisetzung von Medikamenten und dessen Herstellungsmethode.
AR015524A1 (es) FORMULACIoN ESTABLE DE SOLUCIoN DE OXIPLATINO, SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO, PROCESO PARA SU PREPARACIoN, PRODUCTO FARMACÉUTICO QUE LA CONTIENE Y UN MÉTODO PARA ESTABILIZAR UNA SOLUCIoN DE OXALIPLATINO.
HUT55220A (en) Process for producing pharmaceutical composition suitable for systemic administration through the skin and comprising deprenyl as active ingredient
ES2094781T3 (es) Composicion farmaceutica de microparticulas con liberacion controlada y su proceso de preparacion.
ATE375729T1 (de) Verfahren zur herstellung eines pharmazeutischen kaugummis
ATE179886T1 (de) Pharmazeutische zusammensetzung mit einem schmelzbaren traegermaterial und verfahren zu seiner herstellung
ATE130511T1 (de) Gefriergetrocknete polymerdispersionen und ihre anwendung zur darstellung von arzneimittelzubereitungen mit protrahierter wirkstoffabgabe.
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
NO962088D0 (no) Preparat for in vivo-produksjon av terapeutiske produkter
ATE149826T1 (de) Verfahren zur herstellung von festen pharmazeutischen retardformen
ATE190225T1 (de) Arzneiform zur abgabe von wirkstoffen an wunden
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
ATE249819T1 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
NO20031409D0 (no) Ionestyrkeuavhengig farmasöytiske preparat med langvarig frigivelse
DE69527711D1 (de) Verfahren und apparat zur herstellung von schnelllöslichen dosierungseinheiten und daraus erhältliches produkt

Legal Events

Date Code Title Description
8364 No opposition during term of opposition